Abstract
ABSTRACT The field of multiple sclerosis entered the treatment era in 1993, over a decade ago, and now enjoys the availability of five marketed disease-modifying agents. This is an enviable position, not yet obtained in most other serious neurologic diseases. Despite this, the current agents provide only a modest benefit, and improvements in therapeutic options will be welcome. Therapy of multiple sclerosis centers on immunomodulation and immunosuppression, in keeping with the known immunoregulatory abnormalities in this illness. Treatment consists primarily of use of corticosteroids for acute exacerbations and for disease modification, either interferon or glatiramer acetate. More severe disease can be treated with mitoxantrone. Other agents have been utilized, but the basis for their use is less compelling.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
